355 related articles for article (PubMed ID: 24157714)
1. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.
Smith RC; Lin BK
Curr Opin Support Palliat Care; 2013 Dec; 7(4):352-60. PubMed ID: 24157714
[TBL] [Abstract][Full Text] [Related]
2. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
4. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
5. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
6. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
7. Drugs of Muscle Wasting and Their Therapeutic Targets.
Sakuma K; Yamaguchi A
Adv Exp Med Biol; 2018; 1088():463-481. PubMed ID: 30390265
[TBL] [Abstract][Full Text] [Related]
8. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.
Heineke J; Auger-Messier M; Xu J; Sargent M; York A; Welle S; Molkentin JD
Circulation; 2010 Jan; 121(3):419-25. PubMed ID: 20065166
[TBL] [Abstract][Full Text] [Related]
10. Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting.
Smith RC; Cramer MS; Mitchell PJ; Capen A; Huber L; Wang R; Myers L; Jones BE; Eastwood BJ; Ballard D; Hanson J; Credille KM; Wroblewski VJ; Lin BK; Heuer JG
Mol Cancer Ther; 2015 Jul; 14(7):1661-70. PubMed ID: 25908685
[TBL] [Abstract][Full Text] [Related]
11. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
[TBL] [Abstract][Full Text] [Related]
12. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
13. Past, Present, and Future Perspective of Targeting Myostatin and Related Signaling Pathways to Counteract Muscle Atrophy.
Hoogaars WMH; Jaspers RT
Adv Exp Med Biol; 2018; 1088():153-206. PubMed ID: 30390252
[TBL] [Abstract][Full Text] [Related]
14. Targeting the myostatin signaling pathway to treat muscle wasting diseases.
Han HQ; Mitch WE
Curr Opin Support Palliat Care; 2011 Dec; 5(4):334-41. PubMed ID: 22025090
[TBL] [Abstract][Full Text] [Related]
15. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis.
Lee SJ; Gharbi A; Shin JE; Jung ID; Park YM
Biochem Biophys Res Commun; 2021 Mar; 543():1-7. PubMed ID: 33588136
[TBL] [Abstract][Full Text] [Related]
16. Targeting myostatin for therapies against muscle-wasting disorders.
Tsuchida K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
[TBL] [Abstract][Full Text] [Related]
17. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
18. Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro.
Ge Z; Liu D; Shang Y; Li Y; Chen SZ
J Nat Med; 2020 Sep; 74(4):741-749. PubMed ID: 32601830
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
20. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
